Cargando…

Phase 1 Study Evaluating the Effects of the Proton Pump Inhibitor Rabeprazole and Food on the Pharmacokinetics of Lorlatinib in Healthy Participants

Lorlatinib is approved worldwide as treatment for anaplastic lymphoma kinase‐positive and c‐ros oncogene 1‐positive non‐small cell lung cancer. The objectives of this phase 1, open‐label crossover study (NCT02569554) in healthy adult participants were to determine (1) the effects of the proton pump...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Huiping, O'Gorman, Melissa T., Nepal, Sunil, James, Lee P., Ginman, Katherine, Pithavala, Yazdi K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292600/ https://www.ncbi.nlm.nih.gov/pubmed/34288547 http://dx.doi.org/10.1002/cpdd.1000

Ejemplares similares

Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants
por: Hibma, Jennifer E., et al.
Publicado: (2021)

Correction to: Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants
por: Hibma, Jennifer E., et al.
Publicado: (2022)

Evaluation of Proton Pump Inhibitor Esomeprazole on Crizotinib Pharmacokinetics in Healthy Participants
por: Xu, Huiping, et al.
Publicado: (2021)

The Effect of Modafinil on the Safety and Pharmacokinetics of Lorlatinib: A Phase I Study in Healthy Participants
por: Li, Jerry, et al.
Publicado: (2021)

A Phase I Study to Evaluate the Pharmacokinetics and Safety of Lorlatinib in Adults with Mild, Moderate, and Severe Renal Impairment
por: Lin, Swan, et al.
Publicado: (2022)

Correction to: A Phase I Study to Evaluate the Pharmacokinetics and Safety of Lorlatinib in Adults with Mild, Moderate, and Severe Renal Impairment
por: Lin, Swan, et al.
Publicado: (2022)

Population pharmacokinetic model with time‐varying clearance for lorlatinib using pooled data from patients with non‐small cell lung cancer and healthy participants
por: Chen, Joseph, et al.
Publicado: (2021)

Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study
por: Chen, Joseph, et al.
Publicado: (2021)

Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole
por: Ochoa, Dolores, et al.
Publicado: (2020)

Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition
por: Sun, Steven, et al.
Publicado: (2022)

Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer
por: Bauer, Todd M., et al.
Publicado: (2020)

Development of a Fast Onset Proton Pump Inhibitor: Comparison of Fixed-Dose Combination of Rabeprazole and Sodium Bicarbonate (YPI-011) to the Conventional Enteric-Coated Rabeprazole
por: Bae, Sungyeun, et al.
Publicado: (2023)

Impact of Rabeprazole on APO-Dabigatran Exposure in Healthy Volunteers
por: Chan, Noel, et al.
Publicado: (2022)

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers
por: Pithavala, Yazdi K., et al.
Publicado: (2010)

Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors
por: Shin, Jai Moo, et al.
Publicado: (2013)

Exploring Differences in Pharmacometrics of Rabeprazole between Genders via Population Pharmacokinetic–Pharmacodynamic Modeling
por: Jeong, Seung-Hyun, et al.
Publicado: (2023)

Early effect on intragastric pH of oral administration of rabeprazole with mosapride compared with rabeprazole alone
por: Iida, Hiroshi, et al.
Publicado: (2017)

Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study
por: Kinoshita, Yoshikazu, et al.
Publicado: (2017)

In Vitro Effects of Rabeprazole on Human Pylorus Tone
por: Yaşar, Necdet Fatih, et al.
Publicado: (2015)

The underlying mechanisms of lorlatinib penetration across the blood‐brain barrier and the distribution characteristics of lorlatinib in the brain
por: Chen, Wei, et al.
Publicado: (2020)

Stability-indicating HPLC–DAD methods for determination of two binary mixtures: Rabeprazole sodium–mosapride citrate and rabeprazole sodium–itopride hydrochloride
por: El-Fatatry, Hamed M., et al.
Publicado: (2014)

Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update
por: Wedemeyer, Ralph-Steven, et al.
Publicado: (2014)

A review of rabeprazole in the treatment of acid-related diseases
por: Pace, Fabio, et al.
Publicado: (2007)

Effect of rabeprazole on the transport and distribution of levofloxacin in rat stomachs
por: BAO, JUNJUN, et al.
Publicado: (2014)

Multiple widespread fixed drug eruption caused by rabeprazole
por: Gupta, S, et al.
Publicado: (2020)

Pharmacokinetic Study and Tissue Distribution of Lorlatinib in Mouse Serum and Tissue Samples by Liquid Chromatography-Mass Spectrometry
por: Chen, Wei, et al.
Publicado: (2019)

Proton Pump Inhibitors in Pediatrics: Mechanism of Action, Pharmacokinetics, Pharmacogenetics, and Pharmacodynamics
por: Ward, Robert M., et al.
Publicado: (2013)

Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers
por: Pithavala, Y. K., et al.
Publicado: (2009)

Lorlatinib for non-small cell lung cancer
Publicado: (2020)

Evaluation and Management of Dyslipidemia in Patients Treated with Lorlatinib
por: Blais, Normand, et al.
Publicado: (2021)

Podcast on the Management of Adverse Events Associated with Lorlatinib
por: Bauer, Todd M., et al.
Publicado: (2022)

Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study
por: Shaik, Naveed, et al.
Publicado: (2018)

Efficacy and Safety Profile of Z-215 (Azeloprazole Sodium), a Proton Pump Inhibitor, Compared with Rabeprazole Sodium in Patients with Reflux Esophagitis: A Phase II, Multicenter, Randomized, Double-Blind, Comparative Study
por: Kinoshita, Yoshikazu, et al.
Publicado: (2018)

Pharmacokinetics and Excretion Studies on CDRI-85/92, an Antiulcer Proton Pump Inhibitor
por: Srivastava, Pratima
Publicado: (2012)

Quantitative Estimation of Itopride Hydrochloride and Rabeprazole Sodium from Capsule Formulation
por: Pillai, S., et al.
Publicado: (2008)

Ten mg dexrabeprazole daily is as effective as 20 mg rabeprazole daily
por: Kanakia, Rajendra, et al.
Publicado: (2008)

Rabeprazole exhibits antiproliferative effects on human gastric cancer cell lines
por: GU, MENGLI, et al.
Publicado: (2014)

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
por: Mizuta, Hayato, et al.
Publicado: (2021)

Recent Advances in the Management of Adverse Events Associated with Lorlatinib
por: Liao, Dehua, et al.
Publicado: (2023)

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
por: Frost, Charles, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_bjt3c4n6t0mqglogmc0c0tnfu8